{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360002218323019648.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1872-034x.2012.00998.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2012.00998.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2012.00998.x"}},{"identifier":{"@type":"NAID","@value":"20001566659"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>With the increasing use of potent immunosuppressive therapy, reactivation of hepatitis B virus (HBV) in endemic regions is becoming a clinical problem requiring special attention. A recent annual nationwide survey clarified that HBV reactivation related to immunosuppressive therapy has been increasing in patients with malignant lymphoma, other hematological malignancies, oncological or rheumatological disease. In the survey, rituximab plus steroid‐containing chemotherapy was identified as a risk factor for HBV reactivation in hepatitis B surface antigen (HBsAg) negative patients with malignant lymphoma. In this setting, HBV reactivation resulted in fatal fulminant hepatitis regardless of the treatment of nucleoside analog. The Intractable Hepatobiliary Disease Study Group and the Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis jointly developed guidelines for preventing HBV reactivation. The essential features of the guideline are as follows. All patients should be screened for HBsAg by a sensitive method before the start of immunosuppressive therapy. Second, hepatitis B core antigen (HBcAb) and hepatitis B surface antibody (HBsAb) testing should be performed in HBsAg negative patients, especially those receiving intensive immunosuppressive therapy. Prophylaxis with nucleoside analogs is essential for preventing HBV reactivation in HBsAg positive patients. In contrast, HBsAg negative with HBcAb and/or HBsAb positive patients should be monitored monthly for an increase in serum HBV DNA during and 12 months after completion of chemotherapy. Nucleoside analogs should be administrated immediately when HBV DNA becomes positive during this period. This strategy facilitates commencement of nucleoside analogs at an early stage of HBV reactivation and results in prevention of severe hepatitis.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1030003658395401088","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50274816"},{"@type":"NRID","@value":"1000050274816"},{"@type":"NRID","@value":"9000020926510"},{"@type":"NRID","@value":"9000240108368"},{"@type":"NRID","@value":"9000001883673"},{"@type":"NRID","@value":"9000002887470"},{"@type":"NRID","@value":"9000243890274"},{"@type":"NRID","@value":"9000001503859"},{"@type":"NRID","@value":"9000399375282"},{"@type":"NRID","@value":"9000022066520"},{"@type":"NRID","@value":"9000411808378"},{"@type":"NRID","@value":"9000022105900"},{"@type":"NRID","@value":"9000347091075"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0184760"}],"foaf:name":[{"@value":"Makoto Oketani"}]},{"@id":"https://cir.nii.ac.jp/crid/1420282801184833536","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"30291545"},{"@type":"NRID","@value":"1000030291545"},{"@type":"NRID","@value":"9000305640947"},{"@type":"NRID","@value":"9000283273565"},{"@type":"NRID","@value":"9000356552289"},{"@type":"NRID","@value":"9000370277823"},{"@type":"NRID","@value":"9000283478023"},{"@type":"NRID","@value":"9000411237527"},{"@type":"NRID","@value":"9000367422488"},{"@type":"NRID","@value":"9000317151757"},{"@type":"NRID","@value":"9000345347638"},{"@type":"NRID","@value":"9000356667760"},{"@type":"NRID","@value":"9000005808331"},{"@type":"NRID","@value":"9000018883971"},{"@type":"NRID","@value":"9000403149589"},{"@type":"NRID","@value":"9000375886561"},{"@type":"NRID","@value":"9000404101288"},{"@type":"NRID","@value":"9000241519782"},{"@type":"NRID","@value":"9000391588960"},{"@type":"NRID","@value":"9000319049225"},{"@type":"NRID","@value":"9000256350292"},{"@type":"NRID","@value":"9000375849827"},{"@type":"NRID","@value":"9000345403070"},{"@type":"NRID","@value":"9000399375283"},{"@type":"NRID","@value":"9000396113975"},{"@type":"NRID","@value":"9000022066522"},{"@type":"NRID","@value":"9000411808370"},{"@type":"NRID","@value":"9000020429177"},{"@type":"NRID","@value":"9000386307135"},{"@type":"NRID","@value":"9000242669554"},{"@type":"NRID","@value":"9000278479476"},{"@type":"NRID","@value":"9000377381633"},{"@type":"NRID","@value":"9000318138033"},{"@type":"NRID","@value":"9000347091076"}],"foaf:name":[{"@value":"Akio Ido"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003446552312065","@type":"Researcher","foaf:name":[{"@value":"Hirofumi Uto"}]},{"@id":"https://cir.nii.ac.jp/crid/1420845751152480256","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"60145480"},{"@type":"NRID","@value":"1000060145480"},{"@type":"NRID","@value":"9000020926513"},{"@type":"NRID","@value":"9000300215495"},{"@type":"NRID","@value":"9000242086277"},{"@type":"NRID","@value":"9000021871693"},{"@type":"NRID","@value":"9000005808337"},{"@type":"NRID","@value":"9000020411190"},{"@type":"NRID","@value":"9000242082356"},{"@type":"NRID","@value":"9000021468772"},{"@type":"NRID","@value":"9000021482434"},{"@type":"NRID","@value":"9000242077392"},{"@type":"NRID","@value":"9000256568415"},{"@type":"NRID","@value":"9000021545239"},{"@type":"NRID","@value":"9000347038255"},{"@type":"NRID","@value":"9000347120618"},{"@type":"NRID","@value":"9000243890185"},{"@type":"NRID","@value":"9000266899147"},{"@type":"NRID","@value":"9000256349426"},{"@type":"NRID","@value":"9000021488785"},{"@type":"NRID","@value":"9000020594180"},{"@type":"NRID","@value":"9000020593233"},{"@type":"NRID","@value":"9000258037291"},{"@type":"NRID","@value":"9000309562708"},{"@type":"NRID","@value":"9000020412127"},{"@type":"NRID","@value":"9000020535808"},{"@type":"NRID","@value":"9000391969495"},{"@type":"NRID","@value":"9000258205419"},{"@type":"NRID","@value":"9000258017904"},{"@type":"NRID","@value":"9000397435786"},{"@type":"NRID","@value":"9000253567369"},{"@type":"NRID","@value":"9000020562596"},{"@type":"NRID","@value":"9000283328232"},{"@type":"NRID","@value":"9000241881771"},{"@type":"NRID","@value":"9000391969532"},{"@type":"NRID","@value":"9000256350290"},{"@type":"NRID","@value":"9000375849832"},{"@type":"NRID","@value":"9000391978536"},{"@type":"NRID","@value":"9000022066526"},{"@type":"NRID","@value":"9000411808382"},{"@type":"NRID","@value":"9000256377300"},{"@type":"NRID","@value":"9000258559003"},{"@type":"NRID","@value":"9000415049034"},{"@type":"NRID","@value":"9000020563691"},{"@type":"NRID","@value":"9000391973139"},{"@type":"NRID","@value":"9000360588668"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0048913"}],"foaf:name":[{"@value":"Hirohito Tsubouchi"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13866346"},{"@type":"EISSN","@value":"1872034X"}],"prism:publicationName":[{"@value":"Hepatology Research"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2012-06-12","prism:volume":"42","prism:number":"7","prism:startingPage":"627","prism:endingPage":"636"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2012.00998.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2012.00998.x"}],"createdAt":"2012-03-08","modifiedAt":"2023-10-15","project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782124422016","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"22590742"},{"@type":"JGN","@value":"JP22590742"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22590742/"}],"notation":[{"@language":"ja","@value":"遺伝子改変動物を用いた炎症性肝発癌におけるオステオアクチビンの役割の解析"},{"@language":"en","@value":"Involvement of osteoactivin in inflammatory hepatocarcinogenesis: analysis of mice lacking osteoacitivin expression"}]},{"@id":"https://cir.nii.ac.jp/crid/1040282257122216064","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"23249043"},{"@type":"JGN","@value":"JP23249043"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23249043/"}],"notation":[{"@language":"ja","@value":"プロテオミクスを用いた難治性消化器疾患の病態解明と新規診断・治療法の確立"},{"@language":"en","@value":"Using proteomics to elucidate pathogenesis and establish new diagnostic or treatment evaluation methods in refractory gastrointestinal diseases"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050282813895513856","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1050845763845312000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region"}]},{"@id":"https://cir.nii.ac.jp/crid/1050850247217354496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002215326388096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004230127107328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757644928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Etiology and prognosis of fulminant hepatitis and late‐onset hepatic failure in <scp>J</scp>apan: Summary of the annual nationwide survey between 2004 and 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011143708268416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144011577472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus DNA contains a glucocorticoid-responsive element."}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144894619776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145278565888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145818484992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283691771810304","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285705164512640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706510777856","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710588048384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Changing etiologies and outcomes of acute liver failure: A perspective from Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710779454464","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effect of steroid pulse therapy on post‐transplant immunoglobulin A nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711733152384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620395491712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181473724928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185479120640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186831729408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Significance of Hepatitis B Virus (HBV) -DNA Monitoring to Detect HBV Reactivation After Systemic Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094067197824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094568536064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094632531456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095165151360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256755584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848659183561088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660454235392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis <scp>B</scp> virus in a patient with adult <scp>T</scp>‐cell leukemia–lymphoma receiving the anti‐<scp>CC</scp> chemokine receptor 4 antibody mogamulizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661810190848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Is Antiviral Prophylaxis Necessary to Prevent Hepatitis B Virus (HBV) Reactivation in Patients With HBV-Resolved Infection Receiving Rituximab-Containing Chemotherapy?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664146523648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664422559104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568452854528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569591285760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861295165450880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mutation of the “a” Determinant of HBsAg with Discordant HBsAg Diagnostic Kits"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861705581553152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865816802258688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043996583296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective Analysis of Hepatitis B Virus Reactivation in Patients With Diffuse Large B-Cell Lymphoma After Rituximab Combination Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044487250816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Occult hepatitis B virus infection and its clinical implications"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044530342784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045436302080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518874700928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving Rituximab"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519337893504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519776089856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chemotherapy and Bone Marrow Transplantation for Cancer Patients Who Are Also Chronic Hepatitis B Carriers: A Review of the Problem"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520552559104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520921791872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-lasting memory T cell responses following self-limited acute hepatitis B."}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521133119360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993392772992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Spontaneous relapse of hepatitis in inactive HBsAg carriers"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994988635904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468351019136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chronic hepatitis B: Update 2009 #"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469479239808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470152682112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470748217728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470909605632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944973874048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946002022272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418835120000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419292936576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420245069568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420499971072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421171752576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis viruses under immunosuppressive agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893477460736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893771478272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reverse Seroconversion of Hepatitis B Virus after Hematopoietic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894374220928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895818995456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896007630976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rituximab treatment results in impaired secondary humoral immune responsiveness"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368743206784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369564771712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370306839296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843277841280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843666661120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844608643968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844708377216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844884561536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845499188352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845972566784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318499894784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evaluation of the patient with hepatitis B #"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318544988672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319693441408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Entecavir resistance is rare in nucleoside naïve patients with hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320396288256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793444013952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794048619392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidemiology and Natural History of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794119795968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795012727296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795160891904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795678848256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269560457344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269927331840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270364220032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Progressive Disappearance of Anti-Hepatitis B Surface Antigen Antibody and Reverse Seroconversion after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Previous Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795610880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis"},{"@language":"ja","@value":"免疫抑制・化学療法により発症するＢ型肝炎対策：厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告"},{"@language":"ja-Kana","@value":"メンエキ ヨクセイ カガク リョウホウ ニ ヨリ ハッショウスル Bガタ カンエン タイサク コウセイ ロウドウショウ ナンチセイ ノ カン タンドウ シッカン ニ カンスル チョウサ ケンキュウ ハン ゲキショウ カンエン ブンカカイ オヨビ カンコウヘン オ フクメタ ウイルスセイ カン シッカン ノ チリョウ ノ ヒョウジュンカ ニ カンスル ケンキュウ ハン ゴウドウ ホウコク"},{"@value":"Prevention of immunosuppressive therapy or chemotherapy‐induced reactivation of hepatitis B virus infection: joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679220206976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771629056","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"急性肝不全：わが国における課題"},{"@language":"en","@value":"Recent status of acute liver failure in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772012160","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A fatal case of acute liver failure with hepatitis B virus genotype D infection"},{"@language":"ja","@value":"B型肝炎ウイルスgenotype D感染または再活性化を契機に急性肝不全で死亡した1例"},{"@value":"症例報告 B型肝炎ウイルスgenotype D感染または再活性化を契機に急性肝不全で死亡した1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク Bガタ カンエンウイルス genotype D カンセン マタハ サイカッセイカ オ ケイキ ニ キュウセイ カンフゼン デ シボウ シタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772150912","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"当院における肝炎ウイルス検査の実施状況と陽性者に対する受診勧奨システム構築による院内連携の変化について"},{"@language":"en","@value":"Promotion of intra-hospital referral of hepatitis B and C virus carriers to hepatology specialists by electronic medical record-based alert system: a case study at a university hospital"},{"@language":"ja-Kana","@value":"トウ イン ニ オケル カンエンウイルス ケンサ ノ ジッシ ジョウキョウ ト ヨウセイシャ ニ タイスル ジュシン カンショウ システム コウチク ニ ヨル インナイ レンケイ ノ ヘンカ ニ ツイテ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564227345401216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B virus recurrence after living donor liver transplantation of anti-HBc-positive grafts: A 22-year experience at a single center"}]},{"@id":"https://cir.nii.ac.jp/crid/1390568456357560192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713049085952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390868826189491200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Delayed Hepatitis B Virus Reactivation at 33 Months after the Completion of Rituximab-based Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387450393235712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"High prevalence of hepatitis B virus infection in B cell non-Hodgkin's lymphoma"},{"@value":"High prevalence of hepatitis B virus infection in B‐cell non‐Hodgkin's lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387451188738176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy"},{"@value":"Doxorubicin activates hepatitis B virus (HBV) replication in HBV‐harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400914174208","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231874740925568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate"},{"@value":"Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen‐negative patient with rheumatoid arthritis receiving low dose methotrexate"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.00998.x"},{"@type":"CIA","@value":"20001566659"},{"@type":"KAKEN","@value":"PRODUCT-13538812"},{"@type":"KAKEN","@value":"PRODUCT-13538829"},{"@type":"KAKEN","@value":"PRODUCT-13830461"},{"@type":"CROSSREF","@value":"10.1002/hep.26963_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.01105.x_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.57.7_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1002/jmv.25011_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1007/s12328-016-0631-1_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1111/nep.13272_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1182/asheducation-2014.1.576_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.56.453_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1587-18_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5179-24_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1007/s12185-015-1750-z_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1111/hepr.13229_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1620/tjem.237.9_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1016/j.jdcr.2018.11.016_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1168-2_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1080/14397595.2018.1472358_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1111/hepr.12117_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5678-20_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.3109/14397595.2013.852834_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.3390/ijms151121455_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.5582/bst.2019.01283_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.748_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1111/jvh.13740_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1093/mr/road098_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1200/jco.2013.52.1278_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"},{"@type":"CROSSREF","@value":"10.1038/ki.2013.291_references_DOI_M6xIsqbtnBcalH9RyGuzfjUlhq7"}]}